Bavarian Nordic to Host Capital Markets Day in New York City
(Thomson Reuters ONE) -
COPENHAGEN, Denmark, September 14, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) will host a capital markets day for institutional investors and equity
analysts on Thursday, September 21, 2017 in New York City.
At this half-day event, the management of Bavarian Nordic will provide an update
on the company's business and future plans and opportunities. Additional
speakers include Dr. James Gulley and Dr. Ravi A. Madan from the National Cancer
Institute and Dr. Douglas McNeel, Associate Professor at the University of
Wisconsin-Madison, who will focus on the Company's oncology programs and the
role of vaccines in the oncology field.
The capital markets day will take place at Le Parker Meridien Hotel, 119 West
56(th) Street, New York City from 08:15 AM EDT to 12:30 PM EDT. Following the
presentations, participants are invited to attend a lunch hosted by Bavarian
Nordic.
For registration and more information please visit www.bavarian-nordic.com/cmd
or contact our investor relations team on investor(at)bavarian-nordic.com.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies and
vaccines for infectious diseases, based on the Company's live virus vaccine
platform. Through long-standing collaborations, including a collaboration with
the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for
infectious diseases, including the non-replicating smallpox vaccine,
IMVAMUNE(®), which is stockpiled for emergency use by the United States and
other governments. The vaccine is approved in the European Union (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its strategic partner
Janssen are developing an Ebola vaccine regimen, and therapeutic vaccines for
HPV, HBV and HIV. Additionally, in collaboration with the National Cancer
Institute, Bavarian Nordic has developed a portfolio of active cancer
immunotherapies, including PROSTVAC(®), which is currently in Phase 3 clinical
development for the treatment of advanced prostate cancer. The company has
partnered with Bristol-Myers Squibb for the potential commercialization of
PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on
Twitter (at)bavariannordic.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
Press Release
2017-09-14-en:
http://hugin.info/100065/R/2134117/816471.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 14.09.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 559966
Anzahl Zeichen: 3264
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 295 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic to Host Capital Markets Day in New York City"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
